ÂÜÀòÂÒÂ×

During his 20 year tenure at Amylin, Orville Kolterman, M.D. was instrumental in the development of first-in-class diabetes medicines, including SYMLIN, and BYETTA, BYDUREON, and Myalept injections. Prior to his appointment as Senior Vice President & Chief Medical Officer, Dr. Kolterman held leadership roles in the regulatory, research, development, clinical, and medical affairs departments, many of which were officer-level positions. Before Amylin, he was Program Director of the General Clinical Research Center and Medical Director of the Diabetes Center at the University of California Medical Center. Dr. Kolterman has served as a board member for the American Diabetes Association (ADA) Research Foundation and is a past President of the California Affiliate of the ADA. He has held the role of Adjunct Professor of Medicine at the University of California, San Diego for over 20 years. Dr. Kolterman earned his medical degree from Stanford University School of Medicine. Dr. Kolterman currently serves as the Chief Medical Officer for Pendulum Therapeutics.